Best OTC Hearing Aids of 2026
Quick answer
Our top-rated OTC hearing aid for 2026 is Apple AirPods Pro 3 with the Hearing Aid feature, scoring 7.8/10, and Firsthand earns nothing on it. FDA granted the feature De Novo authorization in 2024 after a 118-person study found self-fitting gave similar perceived benefit to professional fitting, and at $249 it is the cheapest FDA-authorized option here, though it needs an iPhone or iPad and has a 14-day return window. Jabra Enhance Select (7.7) is the pick for support, with a 100-day trial and 3 years of remote audiology, at $1,195 to $1,995. Concha Sol (7.3) suits people who prefer disposable batteries, and Sennheiser All-Day Clear (7.1) is the lowest-cost dedicated aid at $999.95 but carries only a 1-year warranty. All four are for adults with perceived mild to moderate loss. Sudden or one-sided hearing changes need a clinician.
Since FDA created the over-the-counter hearing aid category in 2022, adults with perceived mild to moderate hearing loss can buy a hearing aid without a prescription or exam. For this 2026 ranking we only considered devices with an FDA authorization we could look up in FDA's own databases, and that the maker still sells. Two well-known brands, Eargo and Lexie, were left out because their websites say their US parent is winding down operations. We scored four options against our published methodology, weighting Safety 30% and Evidence 30%, then Cost & Value 20%, Transparency 10% and Support 10%. Firsthand does not test devices by hand; scores come from regulatory records, published studies and the makers' own terms. The research on self-fitting aids is encouraging but young: a 2026 meta-analysis found outcomes comparable to professional fitting with low certainty, and a 2025 trial found full audiologist care still scored higher. FDA advises seeing a clinician first if you have sudden or one-sided hearing loss, ear pain, drainage or dizziness.
How we scored: every product below was rated 0–10 on five weighted criteria — Safety (30%), Evidence (30%), Cost & Value (20%), Transparency (10%), and Support (10%). Commissions never affect scores or rank order. Read our full methodology.
2026 rankings at a glance
| # | Product | Rating | Best for | Price | Actions |
|---|---|---|---|---|---|
| 1 | Apple AirPods Pro 3 with Hearing Aid featureNot an affiliate — no commission earned | 7.8/10 | iPhone users with perceived mild to moderate hearing loss who want a low-cost first step | $249 (as of 2026-10-02) | |
| 2 | Jabra Enhance Select (M1, M2, M3)Not an affiliate — no commission earned | 7.7/10 | Adults with mild to moderate hearing loss who want a long trial and ongoing audiologist support | $1,195 to $1,995 per pair (as of 2026-10-02) | |
| 3 | Concha Sol OTC Hearing AidsNot an affiliate — no commission earned | 7.3/10 | People who would rather swap a battery weekly than charge nightly | $1,299 per pair (as of 2026-10-02) | |
| 4 | Sennheiser All-Day Clear OTC Hearing AidsNot an affiliate — no commission earned | 7.1/10 | Budget-minded buyers who want a dedicated rechargeable OTC aid without an iPhone | $999.95 per pair (as of 2026-10-02) |
Apple AirPods Pro 3 with Hearing Aid feature
7.8/10The cheapest FDA-authorized route into OTC amplification in this ranking, backed by a device-specific FDA-reviewed study. The trade-offs are an iPhone requirement, earbud-style battery life and a short return window with no audiologist behind it.
- The Hearing Aid feature was granted FDA De Novo authorization (DEN230081) in September 2024 as the first OTC hearing aid software
- Needs AirPods Pro 2 or 3 plus a compatible iPhone or iPad; there is no Android path
Jabra Enhance Select (M1, M2, M3)
7.7/10The strongest support package in this ranking: a 100-day trial, a 3-year warranty and 3 years of remote audiology. It costs four to eight times as much as the Apple option, and the evidence base is for self-fitting OTC aids in general rather than this model.
- Jabra states the M-series self-fitting technology is FDA cleared, and FDA's 510(k) database lists a June 2026 self-fitting OTC clearance for a Jabra Enhance Select model
- The most expensive line here, at $1,195 to $1,995 per pair
Concha Sol OTC Hearing Aids
7.3/10A cleared self-fitting OTC aid with an audiologist video call before you buy and no charger to manage. Price sits at the upper end of the mid-range, and the evidence is class-level.
- FDA 510(k) clearance K233747 (March 2024) as a self-fitting OTC hearing aid
- At $1,299 per pair it costs more than Jabra's entry M1 and more than the Sennheiser option
Sennheiser All-Day Clear OTC Hearing Aids
7.1/10The lowest-cost dedicated hearing aid in this ranking, with a fair 90-day trial. A 1-year warranty, no audiologist package and loose 'FDA-approved' wording hold it back.
- FDA 510(k) clearance K230538 (June 2023) as a self-fitting OTC hearing aid, held by Sonova
- Only a 1-year manufacturer warranty, the shortest here
Frequently asked questions
Who should buy an OTC hearing aid?
FDA says OTC hearing aids are for adults 18 and older with perceived mild to moderate hearing loss, the kind where you hear in quiet but struggle in groups or noise. They have limited maximum output and may not be enough for severe loss.
Are self-fitting OTC hearing aids as good as ones fitted by an audiologist?
Close, on average, but not identical. A 2026 meta-analysis of 15 studies found comparable outcomes with low certainty of evidence, while a 2025 randomized trial of 245 adults found audiologist-fitted care scored modestly higher than OTC models.
When should I see a doctor instead?
FDA lists sudden hearing change within the past 6 months, hearing loss worse in one ear, ear drainage, pain or dizziness, and ringing in only one ear as reasons to see a healthcare professional before buying an OTC hearing aid.
Why are Eargo and Lexie not in this ranking?
Both brands' websites carry a notice that their US parent entered an assignment for the benefit of creditors in July 2026 and is winding down, with app support and customer service ending in October 2026. We only rank products that are still sold and supported.
Get evidence-based health picks in your inbox — no hype.
Join The Firsthand Brief for a weekly, research-first read.
We never sell your email. Unsubscribe anytime. See our privacy policy.